(Reuters) - LONDON, July 25 - GlaxoSmithKline Plc more
than doubled its share buyback programme to 12 billion pounds
on Wednesday, boosting its shares even as sliding
sales of diabetes drug Avandia held back second-quarter profit.
Europe's biggest drugmaker kept its forecast for 2007
earnings growth of 8 to 10 percent at constant currencies, but
signalled this depended on results of a U.S. regulatory review
of Avandia after a study said it raised heart attack risks.
Read more at Reuters.com Mergers News
than doubled its share buyback programme to 12 billion pounds
on Wednesday, boosting its shares even as sliding
sales of diabetes drug Avandia held back second-quarter profit.
Europe's biggest drugmaker kept its forecast for 2007
earnings growth of 8 to 10 percent at constant currencies, but
signalled this depended on results of a U.S. regulatory review
of Avandia after a study said it raised heart attack risks.
Read more at Reuters.com Mergers News
No comments:
Post a Comment